Skip to content
Company Terminals IPO Intel Calculators Gold Desk Research Services Roadmap Pricing Get started →
The $13 Billion Machine: Inside the Macro-Economics of the 2026 FIFA World CupAlibaba share price is up 16% today. what next for Baba stock?IPO Allotment status check online by PAN number 2025UnitedHealth (UNH Stock): You should stay away from itQ4 results live updates: Adani Group companies in focusThe $13 Billion Machine: Inside the Macro-Economics of the 2026 FIFA World CupAlibaba share price is up 16% today. what next for Baba stock?IPO Allotment status check online by PAN number 2025UnitedHealth (UNH Stock): You should stay away from itQ4 results live updates: Adani Group companies in focus

Pramodini Medicare

PRAMODINI · Hospital & Healthcare Services · INE2JG601017

Analyst mean 0.00 · 0 analysts · 0% bullish
₹115.00
Close 2026-09-22
Price
₹115.00
Mkt cap
₹254 cr
P/E (TTM)
14.6xexcl. exceptional items
P/B
4.78x
Book value
₹24.0
D/E
0.34
Consolidatedstandalone figures are read separately and never mixed into these tables

What's newsince the last filing we processed

Announcement 9 Sep - Board approved SPV incorporation, Neosoft 32 Slice CT scanner purchase, and internal auditor appointment for FY2026-27. Open

Read from the offer document

This company listed within the last twelve months, so its prospectus is still the primary source. The figures below were extracted from the DRHP and RHP before listing and scored then, and they are shown here as they stand in the IPO record rather than restated.

64/100 88% coverage
₹118 SME platform
₹69.00 cr
+1.7%
high score 8

What the score is made of

Score components
Issue structure70
Financial quality66.9
Valuation vs peers75
Underwriter quality60
Governance forensics52

Flagged in the offer document

Each flag is a fact read in the filing, shown with the context that makes it meaningful.

  • Severe Internal Control Lapses: Missing Loan sanction documents, failure to submit stock statements, and 1,647-day ROC auditor appointment delay flagged
  • Historical Disqualification of Promoters and Directors under Section 164(2) flagged
  • Significant Related Party Dependency: Core Function Outsourcing and Large Loan Receivables flagged
  • Material Off-Balance Sheet Exposure via Corporate Guarantees to Promoter Group Entity flagged
  • Unidentified Inorganic Acquisitions Object Funded by Public Raising noted
  • Massive 12:1 Pre-IPO Bonus Issue Capitalizing Reserves noted
  • High Operating Cash Conversion Profile noted

What the issue was raised for

Stated objects, as worded in the offer document. Deployment against them is tracked separately.

  • Source: p. 97 · Purpose: Funding of capital expenditure for purchase of Medical Equipments towards Existing and Proposed Diagnostic Centres · Amount cr: 45.1485
  • Source: p. 97 · Purpose: General Corporate Purposes
  • Source: p. 97 · Purpose: Unidentified inorganic acquisition

What the company said

Claims made in the offer document, to be read against what the company has reported since.

  • Operates a strategic, independent network of 16 diagnostic centers across 7 states with technical capability and robust IT infrastructure.

Lock-in

  • Period: locked-in for a period of 3 years from the date of allotment · Shares: 4409119 · Source: p. 92, 93 · Category: promoter
  • Period: locked in for a period of two years from the date of allotment in the initial public offer · Shares: 4699979 · Source: p. 93, 94 · Category: promoter
  • Period: locked in for a period of one year from the date of allotment in the initial public offer · Shares: 4699979 · Source: p. 94 · Category: promoter
  • Period: locked in for a period of one year from the date of allotment of Equity Shares in this Offer · Shares: 2385318 · Source: p. 94 · Category: other
  • Period: Fifty percent of the Equity Shares allotted to Anchor Investors under the Anchor Investor Portion shall be locked-in for a period of 90 days from the date of Allotment and the remaining Equity Shares allotted to Anchor Investors under the Anchor Investor Portion shall be locked-in for a period of 30 days from the date of Allotment · Source: p. 94 · Category: financial investor

The business

What it does

Deep

Pramodini Medicare Limited provides a comprehensive range of technology-enabled diagnostic services, including MRI, CT scans, ultrasound, and PET-CT oncology imaging. Originally incorporated on September 12, 2000, as 'Pramodini Medicare Private Limited' in Vijayawada, Andhra Pradesh, the company operates its diagnostic centers primarily from leased premises. Its expansion plans involve setting up proposed diagnostic centers and upgrading existing facilities in locations such as Vijayawada, Bangalore, Hubli, and Manjari. The company has placed medical equipment orders with suppliers like Truevis Technologies Private Limited, but has not yet finalized orders for all proposed diagnostic devices. Its customer base consists of individual patients and healthcare providers utilizing diagnostic services. The company delivers its diagnostic and imaging services directly to patients through its diagnostic centers.

Moat

Strategic presence across various states of India, a strong network with diversified models, technical capability with robust IT infrastructure, and a diverse customer and patient base.

Short: Pramodini Medicare Limited is an Indian diagnostic service provider offering technology-enabled diagnostic and imaging services.

Source: p. 106

Peers named in the document

The comparable set the company chose, which is itself a disclosure.

NameMarginPbPeRoeSource
Pramodini Medicare Limited32.69p. 107
Invicta Diagnostic Limited13.629.76p. 108
Krsnaa Diagnostics Limited16.7410.35p. 108
Star Imaging & Path Labs Limited7.8716.58p. 108

The numbers as filed

Financials

As presented in the offer document. Post-listing figures are in the statements above.

Revenue crPat cr
35.26.93
FY24
38.211
FY25
62.317.4
FY26
The numbers behind it
BasisPeriodRelated party revenue crPat crEbitda crPat marginRevenue crPat margin derived
consolidatedFY260.927117.377330.903527.9%62.2875yes
consolidatedFY250.080511.027620.966128.84%38.2377yes
consolidatedFY240.30166.930115.534719.67%35.2295yes
The questions worth asking

Written before listing, answered from the document itself.

How are the fresh issue proceeds being deployed?

Proceeds are earmarked for funding capital expenditure for the purchase of medical equipment for existing and proposed diagnostic centers (Rs 45.15 Cr). The balance is allocated to general corporate purposes and unidentified inorganic acquisitions, subject to a combined cap of 35% of Gross Proceeds (with unidentified acquisitions limited to

p. 31, 97, 98

Who are the promoters and what is their acquisition cost?

The promoters are Dr. Chalasani Kuldeep Kumar, Dr. Chalasani Kavitha, Ms. Chalasani Durga Aashritha, and M/s. Sri Ram Medicare Private Limited, holding 85.71% pre-issue. Due to a 12:1 bonus issue in March 2026, the weighted average cost of acquisition for secondary transactions stands at Rs 34.95 per equity share.

p. 82, 84, 92, 111, 112, 180

Are there material related-party transactions or balance-sheet exposures?

Yes. The company has given loans to associate Vista Pramodini Medicare Pvt Ltd (outstanding receivable of Rs 7.34 Cr in FY26) and paid Rs 0.61 Cr in manpower charges to Infer Radiological & Imaging Services Pvt Ltd. It has also extended an outstanding corporate guarantee of Rs 4.95 Cr on behalf of promoter group entity Sri Ram Medicare Pvt Ltd.

p. F-2, 333, 334

Does operating cash flow align with reported profits?

Yes, exceptionally well. Operating cash flow (CFO) has consistently exceeded reported PAT over the last three years: FY26 CFO was Rs 25.39 Cr vs PAT of Rs 17.38 Cr; FY25 CFO was Rs 22.12 Cr vs PAT of Rs 11.03 Cr; and FY24 CFO was Rs 9.85 Cr vs PAT of Rs 6.93 Cr. This indicates high earnings quality.

p. 26, 65, 66, 67, 161, 162

What structural market parameters apply to this offer?

The offer consists of a Fresh Issue of up to 53,50,800 shares and an OFS of up to 5,00,400 shares. Shreni Shares Limited and Rainbow Securities Private Limited act as joint market makers (up to 3,36,000 shares reserved). Post-issue capital is structured at Rs 22.05 Cr (2,20,45,595 shares of face value Rs 10 each), allowing listing on the NSE Emerge platform.

p. 1, 8, 9, 61, 71, 79, 327

Valuation at issue

What the issue priced at, on the figures in the document.

p. 107

The offer, ownership and risks

Pre-IPO investors
DateNameSharesPrice per shareCategoryIssue typeSource
2000-09-12Initial Subscribers (Mr. Raja Rao Yalamanchili and Ms. Hymavathi Yalamanchali)2010promoter groupinitialp. 83, 84
2004-03-31Further Allotment9499010otherpreferentialp. 83
2011-03-25Further Allotment90000010otherpreferentialp. 83
2018-03-21Ms. Hymavathi Yalamanchali to Dr. Chalasani Kuldeep Kumar13500080.93promotertransferp. 89
2018-03-21Mr. Raja Rao Yalamanchili to Dr. Chalasani Kuldeep Kumar8001080.93promotertransferp. 89
2018-04-02Ms. Hymavathi Yalamanchali to Dr. Chalasani Kavitha3000080.93promotertransferp. 90
2018-04-02Mr. Raja Rao Yalamanchili to Dr. Chalasani Kavitha9574980.93promotertransferp. 90
2020-02-12Share Sub-division / Split (face value ₹10 to ₹1)othersplitp. 90
2025-03-10Dr. Chalasani Kuldeep Kumar to Mr. Yash Hitesh Patel64212031othertransferp. 91, 111
2025-03-17Dr. Chalasani Kuldeep Kumar to Ms. Sumita Mishra25684031othertransferp. 91, 111
2025-03-30Share Consolidation (face value ₹1 to ₹10)othersplitp. 84, 91
2025-04-02Dr. Chalasani Kuldeep Kumar to Mr. Siva Rama Krishna Prasad Atluri6451310othertransferp. 91, 111
2025-04-02Dr. Chalasani Kuldeep Kumar to Ms. Karri Mani Kumari3225310othertransferp. 111
2025-04-03Dr. Chalasani Kuldeep Kumar to Mr. Swapnil Sudhakarrao Topale3225310othertransferp. 111
Management

Ceo: Dr. Chalasani Kuldeep Kumar

Litigation

TDS demands against the Company: 7 cases u/s Rs 0.0039 Cr. Direct Tax demands against Promoters: 12 cases u/s Rs 0.0151 Cr. Direct Tax demands against Group Companies: 10 cases u/s Rs 0.1008 Cr. Pending Civil Suit u/s Independent Director (Ajay Kumar Attaluri): 1 case (amount unascertainable). Ongoing civil/writ petition against Group Company (Infer Radiological): 1 case (amount unascertainable).

Auditor name: M/s. S S S S & Associates, Chartered Accountants

Skin in game: 85.71%

Auditor rpt flags

Auditor report (Note A u/s secured loans) discloses that underlying sanction letters/loan agreements for certain borrowings were not readily available at the reporting date. Further, Note 17 u/s additional notes indicates that the Company availed borrowings u/s security of current assets but did not submit monthly returns/statements of current assets to banks, preventing reconciliation of material discrepancies.

Auditor changed last 3y: Yes

Source: p. 3, 5, 29, 82, 92, 95, 121, 124, 147, 186, 235, 291, 329, 393

The offer and who ran it
Ownership around the issue
Promoter, pre-issue85.7%
Pledged0%
85.71%
0%
22.05 cr
10
1,200
283,200
Purva Sharegistry (India) Private Limited
Smart Horizon Capital Advisors Private Limited

Price in context split-adjusted

1M
-2.5%
From high
-11.2%
worst -11%
Close 50-DMA 200-DMA own P/E band (median ±1σ)
Trading at 11.1x against its own 10-year median of 11.2x0.2σ below its usual range. This compares the company with its own history, not with other companies.

Numbered markers are corporate actions and, once the filings are read, capital and governance events. Prices are split-adjusted so the series is continuous.

Reading the Statements forensic interpretation

What the numbers mean when read together — computed from the filings, not a score.

Burning cash after capex

Free cash flow is negative — the business consumes more than it generates once capex is paid. Fine if it is deliberate growth investment; a problem if it is structural.

Why this reading: Noted with caution — worth watching, but not yet conclusive on its own. Business has ups and downs; one soft reading is not a verdict.

Full read

Latest free cash flow ₹-4 cr, negative in 1 of 3 years. Check whether the burn funds expansion (dark stores, plants, ports) or merely sustains operations.

Operating cash flow backs the profit

Operating cash is 147% of trailing profit — the earnings are converting to real cash, not just accruals.

Why this reading: A positive signal: cash conversion at or above ~0.9 means reported profit is showing up as actual cash.

Full read

Operating cash ₹25 cr against trailing net profit ₹17 cr. Consistent conversion near or above 1.0 is a hallmark of genuine earnings.

Borrowing is funding real capacity

Debt rose over 2 years, and most of it (467%) has turned into fixed assets and projects under construction — the borrowing is building the business.

Why this reading: A positive signal: leverage taken on is visibly becoming productive capacity, not disappearing.

Full read

New borrowing ₹6 cr largely matched by an asset build of ₹28 cr. Debt that funds capacity is a different thing from debt that funds nothing.

Forensic modelscomputed from the filed statements

Every score below is calculated here from the reported numbers — none of it is asserted. Open the notebook at the foot of the section to see each formula with this company's figures in it.

Altman Z″

Needs current assets and current liabilities.

Piotroski F

4 / 8 1 not testable
  • Profitable this year
  • Operating cash positive
  • Return on assets improved
  • Cash exceeds profit
  • Leverage reduced
  • Liquidity improved
  • No share dilution
  • Margin improved
  • Assets working harder
What is this, and how do I read it?

Piotroski F-Score — fundamental momentum — Joseph Piotroski, University of Chicago, 2000, in a study of whether accounting signals could improve returns among cheap stocks.

Nine yes-or-no tests across profitability, leverage and operating efficiency. Each pass scores one. It asks a narrow question: is this business getting better or worse on its own terms, year over year?

Profitability (4 tests)
Positive profit, positive operating cash, improving return on assets, and cash exceeding profit. The last is the quality test — profit that outruns cash is the one to question.
Leverage and liquidity (3 tests)
Falling debt, improving current ratio, no new shares issued. Growth funded by dilution scores zero here.
Operating efficiency (2 tests)
Improving margin and improving asset turnover.

How to read it7 or more suggests improving fundamentals; 3 or fewer suggests deterioration. It measures direction, not quality — a weak company improving can score higher than a strong one holding steady.

Where it failsA single year of comparison, so one unusual year distorts it. Says nothing about valuation, competitive position or management. Piotroski designed it to rank already-cheap stocks, not to judge a company in isolation.

Beneish M

Needs trade receivables, current assets, other expenses.

Cash vs profit

1.63× 3-year cumulative

Accruals are -10.7% of assets. Free cash flow negative in 1 of 3 years.

DuPont — return on equity FY2026

Net margin27.4%× Asset turnover0.66×× Leverage1.77×= ROE32.1%
What is this, and how do I read it?

DuPont decomposition — Devised inside the DuPont Corporation in the 1920s and still the standard way to read a return on equity.

Splits return on equity into its three sources, so the same headline number can be traced to very different businesses.

Net margin
What the company keeps from each rupee of sales. High margin points to pricing power or a genuine cost advantage.
Asset turnover
Sales generated per rupee of assets. High turnover points to efficiency — a retailer earns this way, a utility never will.
Leverage (equity multiplier)
Assets divided by equity. This multiplies whatever the first two produce, in both directions.

How to read itA 20% ROE built on margin and turnover is a different proposition from a 20% ROE built on 3× leverage. The first survives a downturn; the second amplifies it.

Where it failsA single year. Negative equity makes it meaningless. Leverage is structural for lenders, so the third term carries no signal there.

Leverage & coverage FY2026

Debt / equity0.34×
Interest coverage24.00×
ROCE42.0%

Capital that builds FY2024 → FY2026

Capital deployed+175%
Revenue produced+77%
Still in CWIP₹0 cr

Capital is going in far faster than revenue is coming out. For a business mid-build that is expected — the test is whether it converts.

The formula notebook — every number above, worked out
Cash vs profit cumulative operating cash flow ÷ cumulative net profit ₹57 cr ÷ ₹35 cr, over 3 years 1.63× Above 1.0 means cash exceeds reported profit — the healthier reading.
Accruals (Sloan) (net profit − operating cash flow) ÷ average total assets (₹17 − ₹25) cr ÷ average assets -10.7% Negative means cash exceeded profit — the healthier reading. Positive above ~10% is where accruals start to dominate earnings.
DuPont — return on equity net margin × asset turnover × leverage 27.4% × 0.66 × 1.77 32.1% Splits ROE into whether returns come from operations or from borrowing.
Interest coverage EBIT ÷ finance cost ₹24 cr ÷ ₹1 cr 24.00× How many times operating profit covers the interest bill.
Debt to equity borrowings ÷ net worth ₹18 cr ÷ ₹53 cr 0.34× Read against the sector — infrastructure carries more than software.
Capital that builds growth in fixed assets + CWIP, against growth in revenue capital +175% vs revenue +77%, FY2024 to FY2026 98pp gap Money going in far faster than revenue coming out. For an incubator this is expected — the test is whether it eventually converts.

Going deepersame statements, harder questions

Montier C-Score

Needs more balance-sheet detail (only 3 of 6 flags testable).

Return on invested capital FY2026

ROIC25.4%
Capital employed₹71 cr

NOPAT over equity plus debt less cash, at a notional 25% tax. Incremental ROIC is the return on money put in since then — the number that decides whether growth creates value or consumes it.

What is this, and how do I read it?

Return on invested capital, and incremental ROIC — Standard in corporate finance; the incremental form was popularised by Michael Mauboussin as the test of whether growth creates value.

ROIC measures what the business earns on all the capital it employs — equity plus debt, less cash. Incremental ROIC asks a sharper question: what has it earned on the money put in since a chosen year?

NOPAT
Operating profit after a notional tax charge, so the figure is independent of how the company is financed. We use 25%.
Invested capital
Equity plus borrowings less cash — the money actually at work.
Incremental ROIC
Change in NOPAT divided by change in invested capital. If it sits below the cost of capital, growth is destroying value however fast revenue rises.

How to read itROIC comfortably above the cost of capital — call it 11–13% in India — means growth compounds. Below it, growth consumes. Incremental below headline means recent investment is earning less than the legacy business.

Where it failsDistorted in the year of a large acquisition. Understated for companies mid-build, where capital is deployed but capacity has not yet been commissioned — an incubator will look poor until it does not.

Earnings quality ladder FY2026

Cash ÷ EBITDA0.81×
Cash ÷ profit1.47×
Free cash ÷ profit-0.24×

Read downward. Cash can cover EBITDA and still not survive capex — the third rung is where a capital-hungry business shows itself.

What is this, and how do I read it?

The earnings quality ladder — Not a named model — the standard sequence an analyst walks when testing whether reported profit is real.

Three ratios read in order, each stricter than the last.

Cash ÷ EBITDA
Does operating profit arrive as cash? Below 0.8 points to working capital absorbing it.
Cash ÷ profit
Does bottom-line profit arrive as cash? Below 1.0 persistently is the classic warning.
Free cash ÷ profit
Does anything survive capex? This is where capital-hungry businesses reveal themselves — a company can pass the first two and still never generate spendable cash.

How to read itRead downward. Each rung failing where the one above passed tells you exactly where the cash is going.

Where it failsA single year of heavy capex depresses the third rung legitimately. Judge it across a cycle.

Cost of debt FY2026

Interest ÷ average borrowings6.90%
Average borrowings₹15 cr

Against a policy rate near 6%, most sound Indian corporates borrow between 7% and 10%.

What is this, and how do I read it?

Cost of debt — Interest expense over average borrowings — the effective rate the company actually pays.

What the lenders charge, which is a market verdict on credit quality that no rating agency delay affects.

Well below the policy rate
Suggests interest is being capitalised into assets rather than expensed, or that funding comes from related parties on non-market terms.
Near the policy rate plus a normal spread
Ordinary bank funding. Nothing to explain.
Well above
Lenders are pricing risk the equity market may not yet be.

How to read itAgainst a policy rate near 6%, most sound Indian corporates borrow between 7% and 10%. Read the direction over years as much as the level.

Where it failsUnderstated where a large share of interest is capitalised into projects under construction. Not meaningful for lenders, where interest is cost of goods.

Reading the numbers on this pagetwo bases, both shown

What the filings we hold do not give

Models that need these lines are withheld rather than estimated: net worth, current assets, current liabilities, trade receivables, inventory, net block. Nothing on this page is back-solved from a figure the company did not publish.

Published screening frameworksrules applied, not opinions quoted

Each framework below is a set of stated, mechanical criteria from published work, run against this company's own filed numbers. Passing or failing a screen is not a verdict — different frameworks disagree by design, and that disagreement is itself informative.

Graham — defensive investor

3 / 4
  • Debt below net worth ₹18 cr vs ₹53 cr
  • Positive earnings every year 3 of 3 years
  • P/E below 15 14.6×
  • P/E × P/B below 22.5 69.6

Benjamin Graham's stated criteria for a defensive stock, applied to the filed numbers. A company failing several is not disqualified — Graham designed these to be deliberately strict.

Greenblatt — magic formula

1 / 2
  • Return on capital above 20% 33.8%
  • Earnings yield above 8% 6.9%

Two ratios only: what the business earns on its capital, and what you pay for those earnings. Designed to be ranked across a universe rather than read in isolation.

O'Neil — CAN SLIM growth tests

2 / 4
  • Annual earnings growth above 25% -88%
  • Revenue growth above 20% 63%
  • Return on equity above 17% 32.1%
  • Share count not expanding equity capital ₹17 cr

The fundamental half of William O'Neil's framework. The market and leadership components are judgement calls and are not scored here.

Quality — compounder tests

4 / 4
  • Cash conversion above 0.9× 1.63× over 3 years
  • ROCE above 15% 42.0%
  • Interest covered more than 4× 24.00×
  • Debt below half of equity 0.34×

The characteristics long-term holders commonly look for: cash-backed earnings, high returns on capital, and debt that never forces a decision.

The page in pictures

Revenue and what it leaves behind

Bars are revenue; the line is net margin. Revenue rising while the line falls is the shape worth noticing.

FY24 · 35FY24FY25 · 38FY25FY26 · 62FY26
Revenue (₹ cr)Net margin %

Where the year's cash went — FY2026

Operating cash first, then what the business spent and raised.

25Operating cash−31Investing6Financing

Quality over time

One year is a snapshot. These are the two lines that matter across a cycle.

4.53.42.21.1FY24FY25FY26
Cash ÷ profit (×)ROCE (÷10)

Where cash gets stuck

Rising debtor or inventory days against flat sales is the earliest visible sign of stress.

19616112792FY24FY25FY26
Debtor daysCash cycle
Growth & valuation workspace

Set your own assumptions and watch the numbers move. A scenario calculator — the outputs are the arithmetic of your inputs.

User-driven scenario tool. Implied value and CAGR follow only from the assumptions you set — not a FinMinutes forecast, recommendation, or target price.

Valuation & quality

One canonical set of figures — the same numbers used everywhere else on this page and on the screener.

What you payHow the price compares with earnings, book and sales.
P/E (TTM)
14.6x
trailing 12m, live feed
P/B
4.78x
How it is fundedLeverage and what is returned to shareholders.
Debt / equity
0.34
conservative
Book value / share
₹24.0

Ownership & Skin in the Game

Promoter
FII
DII

Working capital12-year series

Where cash gets stuck. A rising inventory or debtor line against flat sales is the earliest sign of trouble in the numbers.

MeasureFY2024FY2025FY2026
Debtor days
How long customers take to pay
186107102
Cash conversion cycle
Debtor + inventory − payable days
186107102
Working capital days1602
ROCE %
Return on capital employed
41.0%42.0%
Trends

The shape of the business over time (annual) — read the direction, not the single print.

Revenue (₹ cr)
FY202435.0FY202538.0FY202662.0
Net profit (₹ cr)
FY20247.0FY202511.0FY202617.0

Annual Profit & Loss ₹ cr

LineFY2024FY2025FY2026
Revenue from operations353862
Other income101
Depreciation447
Finance cost211
Profit before tax101623
Net profit (owners)71117
EPS (₹)5.4085.8910.41

Exceptional items, total income and EBITDA are read from the filed statements.

Balance Sheet ₹ cr, annual

ItemFY2024FY2025FY2026
Equity Capital1117
Reserves233436
Borrowings121118
Net block162244
CWIP000
Investments000
Total Assets495694

Cash Flow ₹ cr

LineFY2024FY2025FY2026
Cash from operations102225
Cash from investing-1-15-31
Cash from financing-11-26
Free cash flow912-4
Net change in cash-250

Cash from operations is the number profit has to answer to. Free cash flow is what remains after the business pays for its own growth.

Disclosure & evidencewhat the filings actually show

These are coverage counts, not ratings. Each one asks a fixed set of questions of the filings and reports how many the company answered. A company that discloses nothing counts nothing here — that is a statement about the disclosure, not about the business.

Capital discipline

3 of 4 disclosed weighted 7 of 10
What was looked for
  • Profit converts to cash — 1.63× over 3 years
  • Free cash flow not persistently negative — 1 of 3 years negative
  • Capital converts into revenue — capital +175% vs revenue +77%
  • Interest comfortably covered — 24.00×

Others in Hospital & Healthcare Services

The same read, applied to the companies this one competes with.

DISCLAIMER: FinMinutes is a financial data and analytics platform, not a registered investment adviser. Everything here is for educational and informational purposes. Forensic interpretations are computed from disclosed data and are not recommendations. Do your own due diligence.
Chat on WhatsApp